14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study

BACKGROUND: Until now, there is little evidence regarding clinical efficacy of 14-day vonoprazan-based bismuth quadruple therapy (BQT) for Helicobacter pylori (H. pylori) eradication. METHODS: Overall, 65 treatment-naïve patients with H. pylori infection who received 14-day vonoprazan-based BQT regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Feifei, Xu, Wentao, Shi, Xiaoye, Yu, Honglu, Qi, Xingshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518141/
https://www.ncbi.nlm.nih.gov/pubmed/37750104
http://dx.doi.org/10.2147/IJGM.S427450
_version_ 1785109449312043008
author Lu, Feifei
Xu, Wentao
Shi, Xiaoye
Yu, Honglu
Qi, Xingshun
author_facet Lu, Feifei
Xu, Wentao
Shi, Xiaoye
Yu, Honglu
Qi, Xingshun
author_sort Lu, Feifei
collection PubMed
description BACKGROUND: Until now, there is little evidence regarding clinical efficacy of 14-day vonoprazan-based bismuth quadruple therapy (BQT) for Helicobacter pylori (H. pylori) eradication. METHODS: Overall, 65 treatment-naïve patients with H. pylori infection who received 14-day vonoprazan-based BQT regimen (VBCA, n=17) or pantoprazole-based BQT regimen (PBCA, n=48) for H. pylori eradication were retrospectively included. RESULTS: Neither successful H. pylori eradication (88.2% versus 91.7%, p=1.000) nor adverse event (52.9% versus 64.6%, p=0.397) was significantly different between VBCA and PBCA groups. CONCLUSION: Vonoprazan seems to be as effective and safe as pantoprazole during a 14-day BQT regimen in treatment-naïve patients with H. pylori infection.
format Online
Article
Text
id pubmed-10518141
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105181412023-09-25 14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study Lu, Feifei Xu, Wentao Shi, Xiaoye Yu, Honglu Qi, Xingshun Int J Gen Med Short Report BACKGROUND: Until now, there is little evidence regarding clinical efficacy of 14-day vonoprazan-based bismuth quadruple therapy (BQT) for Helicobacter pylori (H. pylori) eradication. METHODS: Overall, 65 treatment-naïve patients with H. pylori infection who received 14-day vonoprazan-based BQT regimen (VBCA, n=17) or pantoprazole-based BQT regimen (PBCA, n=48) for H. pylori eradication were retrospectively included. RESULTS: Neither successful H. pylori eradication (88.2% versus 91.7%, p=1.000) nor adverse event (52.9% versus 64.6%, p=0.397) was significantly different between VBCA and PBCA groups. CONCLUSION: Vonoprazan seems to be as effective and safe as pantoprazole during a 14-day BQT regimen in treatment-naïve patients with H. pylori infection. Dove 2023-09-20 /pmc/articles/PMC10518141/ /pubmed/37750104 http://dx.doi.org/10.2147/IJGM.S427450 Text en © 2023 Lu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Lu, Feifei
Xu, Wentao
Shi, Xiaoye
Yu, Honglu
Qi, Xingshun
14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study
title 14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study
title_full 14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study
title_fullStr 14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study
title_full_unstemmed 14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study
title_short 14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study
title_sort 14-day vonoprazan-based bismuth quadruple therapy for treatment-naïve patients with helicobacter pylori infection: a retrospective comparative study
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518141/
https://www.ncbi.nlm.nih.gov/pubmed/37750104
http://dx.doi.org/10.2147/IJGM.S427450
work_keys_str_mv AT lufeifei 14dayvonoprazanbasedbismuthquadrupletherapyfortreatmentnaivepatientswithhelicobacterpyloriinfectionaretrospectivecomparativestudy
AT xuwentao 14dayvonoprazanbasedbismuthquadrupletherapyfortreatmentnaivepatientswithhelicobacterpyloriinfectionaretrospectivecomparativestudy
AT shixiaoye 14dayvonoprazanbasedbismuthquadrupletherapyfortreatmentnaivepatientswithhelicobacterpyloriinfectionaretrospectivecomparativestudy
AT yuhonglu 14dayvonoprazanbasedbismuthquadrupletherapyfortreatmentnaivepatientswithhelicobacterpyloriinfectionaretrospectivecomparativestudy
AT qixingshun 14dayvonoprazanbasedbismuthquadrupletherapyfortreatmentnaivepatientswithhelicobacterpyloriinfectionaretrospectivecomparativestudy

Ejemplares similares